RU2002123349A - Лиганды тироидного рецептора - производные анилина - Google Patents
Лиганды тироидного рецептора - производные анилинаInfo
- Publication number
- RU2002123349A RU2002123349A RU2002123349/04A RU2002123349A RU2002123349A RU 2002123349 A RU2002123349 A RU 2002123349A RU 2002123349/04 A RU2002123349/04 A RU 2002123349/04A RU 2002123349 A RU2002123349 A RU 2002123349A RU 2002123349 A RU2002123349 A RU 2002123349A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- hydrogen
- inhibitor
- alkyl
- skin
- Prior art date
Links
- VGLJPOKNYGLDTF-UHFFFAOYSA-N CC(C)c(cc(cc1)Oc(c(Cl)c(C)c(NC(CC(O)=O)=O)c2)c2Cl)c1O Chemical compound CC(C)c(cc(cc1)Oc(c(Cl)c(C)c(NC(CC(O)=O)=O)c2)c2Cl)c1O VGLJPOKNYGLDTF-UHFFFAOYSA-N 0.000 description 1
- XVDHPJDRJCDBEQ-UHFFFAOYSA-N CC(C)c(cc(cc1)Oc(c([Br]=C)cc(NC(CCCC(O)=O)=O)c2)c2[Br]=C)c1O Chemical compound CC(C)c(cc(cc1)Oc(c([Br]=C)cc(NC(CCCC(O)=O)=O)c2)c2[Br]=C)c1O XVDHPJDRJCDBEQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Claims (30)
1. Соединение формулы
где Х обозначает кислород (-O-), серу (-S-), карбонил (-СО-), метилен (-СН2-) или -NH-;
Y обозначает -(СН2)n-, где n обозначает целое число от 1 до 5, или -С=С-, который представляет собой цис или транс - изомер;
R1 обозначает галоген, трифторметил или алкил, содержащий 1-6 атомов углерода, или циклоалкил, содержащий 3-7 атомов углерода;
R2 и R3 одинаковы или различны и обозначают водород, галоген, алкил, содержащий 1-4 атома углерода, или циклоалкил, содержащий 3-6 атомов углерода, при этом, по меньшей мере, один из R2 и R3 не обозначает водород;
R4 обозначает водород или низший алкил;
R5 обозначает водород или низший алкил;
R6 обозначает карбоновую кислоту или её эфир или их пролекарства;
R7 обозначает водород или алканоил или ароил или другую группу, способную к биоконверсии с образованием свободной фенольной структуры (где R7 = Н); включая все его стереоизомеры, его пролекарства или его фармацевтически приемлемую соль.
2. Соединение по п.1, отличающееся тем, что Х обозначает кислород.
3. Соединение по п.2, отличающееся тем, что R5 обозначает водород.
4. Соединение по п.3, отличающееся тем, что R1 обозначает изопропил.
5. Соединение по п.3, отличающееся тем, что R2 и R3, каждый, независимо обозначает галоген.
6. Соединение по п.3, отличающееся тем, что R2 и R3, каждый, независимо обозначает алкильную группу.
7. Соединение по п.3, отличающееся тем, что один из R2 и R3 обозначает галоген, а другой обозначает алкильную группу.
8. Соединение по п.3, отличающееся тем, что один из R2 и R3 обозначает галоген, а другой обозначает водород.
9. Соединение по п.3, отличающееся тем, что один из R2 и R3 обозначает алкил, а другой обозначает водород.
10. Соединение по п.3, отличающееся тем, что R2 и R3 независимо обозначают С1, Br, метил или этил.
11. Соединение по п.3, отличающееся тем, что R4 обозначает водород.
12. Соединение по п.3, отличающееся тем, что R4 обозначает метил.
13. Соединение по п.3, отличающееся тем, что Y обозначает - (СН2)n, где n обозначает 1 или 2.
14. Соединение по п.3, отличающееся тем, что Y обозначает цис- или транс-этилен.
20. Способ предупреждения, подавления или лечения заболевания, обусловленного дисфункцией обмена веществ или зависящего от экспрессии Т3 регулируемого гена, заключающийся во введении больному, нуждающемуся в лечении, терапевтически эффективного количества соединения по п.1.
21. Способ по п.20, отличающийся тем, что заболевание, обусловленное дисфункцией обмена веществ или зависящее от экспрессии Т3 регулируемого гена, представляет собой ожирение, гиперхолистеринемию, атеросклероз, депрессию, остеопороз, гипотиреоз, зоб, рак щитовидной железы, глаукому, сердечную аритмию, застойную сердечную недостаточность или поражение или заболевание кожи.
22. Фармацевтическая композиция, содержащая эффективное количество соединения по п.1 или его фармацевтически приемлемой соли и фармацевтически приемлемый носитель.
23. Способ по п.21, отличающийся тем, что поражение или болезнь кожи представляет собой дермальную атрофию, пост-хирургическую гематому, вызываемую воздействием лазера, келоиды, атрофические полоски кожи, целлюлит, огрубевшую кожу, фотохимическое поражение кожи, плоский лихен, ихтиоз, угри, псориаз, болезнь Дернье, экзему, диффузный нейродермит, хлоракне, питириаз и рубцевание кожи.
24. Способ лечения кожного поражения или заболевания путём применения соединения по п.1 в комбинации с ретиноидом или аналогом витамина D.
25. Фармацевтическая композиция, содержащая соединение по п.1 и гиполипидемический агент, антидиабетический агент, антидепрессант, ингибитор резорбции костей, вещество, подавляющее аппетит и/или агент против ожирения.
26. Композиция по п.25, отличающаяся тем, что гиполипидемический агент представляет собой тиазолидиндион, МТР-ингибитор, ингибитор сквален-синтетазы, ингибитор HMG СоА-редуктазы, производное фибриновой кислоты, ингибитор АСАТ, ингибитор всасывания холестерина, ингибитор котранспортёра Na+/желчь в подвздошной кишке, вещество, усиливающее секрецию желчных кислот, и/или никотиновую кислоту или её производное.
27. Композиция по п.25, отличающаяся тем, что гиполипидемический агент представляет собой правастатин, симвастатин, ловастатин, аторвастатин, флувастатин или церивастатин.
28. Композиция по п.25, отличающаяся тем, что соединение присутствует в весовом соотношении с гиполипидемическим агентом или с антидиабетическим агентом, примерно, 0,01: 1 - 300:1.
29. Композиция по п.25, отличающаяся тем, что антидиабетический агент представляет собой бигуанид, сульфонилмочевину, ингибитор глюкозидазы, тиазолидиндион, сенсибилизатор инсулина, глюкагоноподобныйпептид-1 (GLP-1) или инсулин.
30. Композиция по п.29, отличающаяся тем, что антидиабетический агент представляет собой метформин, глибурид, глимепирид, глипирид, глипизид, хлорпропамид, гликлазид, акарбозу, миглитол, троглитазон, пиоглитазон, розиглитазон и/или инсулин.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18322300P | 2000-02-17 | 2000-02-17 | |
US60/183,223 | 2000-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2002123349A true RU2002123349A (ru) | 2004-01-10 |
RU2260586C2 RU2260586C2 (ru) | 2005-09-20 |
Family
ID=22671959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002123349/04A RU2260586C2 (ru) | 2000-02-17 | 2001-01-12 | Лиганды тироидного рецептора - производные анилина |
Country Status (30)
Country | Link |
---|---|
US (2) | US6800605B1 (ru) |
EP (1) | EP1257526B1 (ru) |
JP (1) | JP4629294B2 (ru) |
KR (1) | KR100740383B1 (ru) |
CN (1) | CN1216857C (ru) |
AR (1) | AR031094A1 (ru) |
AT (1) | ATE295348T1 (ru) |
AU (2) | AU2001230929B2 (ru) |
BR (1) | BR0108134A (ru) |
CA (1) | CA2400486C (ru) |
CO (1) | CO5271672A1 (ru) |
CZ (1) | CZ20022771A3 (ru) |
DE (1) | DE60110753T2 (ru) |
DK (1) | DK1257526T3 (ru) |
EG (1) | EG25009A (ru) |
ES (1) | ES2242723T3 (ru) |
HK (1) | HK1047925B (ru) |
HU (1) | HUP0301777A3 (ru) |
IL (2) | IL150449A0 (ru) |
MX (1) | MXPA02007929A (ru) |
MY (1) | MY124534A (ru) |
NO (1) | NO329639B1 (ru) |
NZ (1) | NZ520023A (ru) |
PE (1) | PE20020767A1 (ru) |
PL (1) | PL201790B1 (ru) |
PT (1) | PT1257526E (ru) |
RU (1) | RU2260586C2 (ru) |
UY (1) | UY26581A1 (ru) |
WO (1) | WO2001060784A1 (ru) |
ZA (1) | ZA200206072B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
DE10131462A1 (de) * | 2001-06-29 | 2003-01-09 | Bayer Ag | Phenol-Derivate |
US6806381B2 (en) | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
US20040242594A1 (en) * | 2001-11-17 | 2004-12-02 | Dan Peters | Prodrugs of antidepressants and their use for treating depressions |
GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
EP1660090B1 (en) * | 2003-08-14 | 2012-11-21 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
GB0406378D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
GB0606201D0 (en) | 2006-03-28 | 2006-05-10 | Karobio Ab | Improved crytalline material |
GB0606212D0 (en) * | 2006-03-28 | 2006-05-10 | Karobio Ab | Pharmaceutical compositions |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
GB0724478D0 (en) * | 2007-12-14 | 2008-01-30 | Karobio Ab | Pharmaceutical compositions |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
US8922530B2 (en) * | 2010-01-06 | 2014-12-30 | Apple Inc. | Communicating stylus |
EP2609910A1 (en) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Formulations of eprotirome |
PL2695611T3 (pl) | 2012-08-06 | 2015-03-31 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
CN113277958A (zh) * | 2016-05-18 | 2021-08-20 | 俄勒冈健康科学大学 | 苏比替罗衍生物 |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
EP3768690A4 (en) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND |
CN113423684A (zh) * | 2018-12-12 | 2021-09-21 | 速通医疗公司 | 新型拟甲状腺素药 |
WO2020169069A1 (en) | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
KR20230048481A (ko) | 2020-06-02 | 2023-04-11 | 쳉두 캉홍 파마슈티칼 코., 엘티디. | 새로운 갑상선 호르몬 β 수용체 효능제 |
WO2023177667A1 (en) * | 2022-03-16 | 2023-09-21 | Brii Biosciences, Inc. | Thyroid hormone receptor agonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1078582B (de) * | 1958-10-29 | 1960-03-31 | Hoechst Ag | Verfahren zur Herstellung substituierter Thyropropionsaeuren |
JPS6061747A (ja) * | 1983-09-16 | 1985-04-09 | Konishiroku Photo Ind Co Ltd | 熱現像感光材料 |
ES2108855T3 (es) | 1992-07-21 | 1998-01-01 | Ciba Geigy Ag | Derivados de acido oxamico como agentes hipocolesteremicos. |
GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
NZ513449A (en) | 1999-03-01 | 2004-02-27 | Pfizer Prod Inc | Oxamic acids and derivatives as thyroid receptor ligands |
ES2234523T3 (es) | 1999-03-01 | 2005-07-01 | Pfizer Products Inc. | Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos. |
CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
DK1088819T3 (da) | 1999-09-30 | 2005-09-12 | Pfizer Prod Inc | 6-azauracilderivater som thyroidreceptorligander |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
ATE382602T1 (de) * | 2000-03-31 | 2008-01-15 | Pfizer Prod Inc | Malonsäureamide sowie deren derivate als thyroidrezeptor liganden |
AU4884701A (en) * | 2000-05-12 | 2001-11-20 | Kissei Pharmaceutical Co. Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and usethereof |
WO2002094319A1 (en) * | 2001-05-18 | 2002-11-28 | Kissei Pharmaceutical Co., Ltd. | Preventive or recurrence-suppressive agents for liver cancer |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
-
2001
- 2001-01-12 BR BR0108134-9A patent/BR0108134A/pt not_active Application Discontinuation
- 2001-01-12 CZ CZ20022771A patent/CZ20022771A3/cs unknown
- 2001-01-12 JP JP2001559838A patent/JP4629294B2/ja not_active Expired - Fee Related
- 2001-01-12 AU AU2001230929A patent/AU2001230929B2/en not_active Ceased
- 2001-01-12 CN CN018050689A patent/CN1216857C/zh not_active Expired - Fee Related
- 2001-01-12 ES ES01903064T patent/ES2242723T3/es not_active Expired - Lifetime
- 2001-01-12 EP EP01903064A patent/EP1257526B1/en not_active Expired - Lifetime
- 2001-01-12 AU AU3092901A patent/AU3092901A/xx active Pending
- 2001-01-12 HU HU0301777A patent/HUP0301777A3/hu unknown
- 2001-01-12 RU RU2002123349/04A patent/RU2260586C2/ru not_active IP Right Cessation
- 2001-01-12 PL PL366149A patent/PL201790B1/pl not_active IP Right Cessation
- 2001-01-12 MX MXPA02007929A patent/MXPA02007929A/es active IP Right Grant
- 2001-01-12 PT PT01903064T patent/PT1257526E/pt unknown
- 2001-01-12 DK DK01903064T patent/DK1257526T3/da active
- 2001-01-12 CA CA2400486A patent/CA2400486C/en not_active Expired - Fee Related
- 2001-01-12 KR KR1020027010684A patent/KR100740383B1/ko not_active IP Right Cessation
- 2001-01-12 WO PCT/US2001/001204 patent/WO2001060784A1/en active IP Right Grant
- 2001-01-12 NZ NZ520023A patent/NZ520023A/en not_active IP Right Cessation
- 2001-01-12 DE DE60110753T patent/DE60110753T2/de not_active Expired - Lifetime
- 2001-01-12 AT AT01903064T patent/ATE295348T1/de active
- 2001-01-12 IL IL15044901A patent/IL150449A0/xx active IP Right Grant
- 2001-01-16 US US09/761,050 patent/US6800605B1/en not_active Expired - Lifetime
- 2001-01-31 MY MYPI20010445A patent/MY124534A/en unknown
- 2001-02-14 EG EG20010132A patent/EG25009A/xx active
- 2001-02-14 UY UY26581A patent/UY26581A1/es not_active Application Discontinuation
- 2001-02-15 CO CO01012101A patent/CO5271672A1/es not_active Application Discontinuation
- 2001-02-16 AR ARP010100730A patent/AR031094A1/es active IP Right Grant
- 2001-02-16 PE PE20010001762002000058A patent/PE20020767A1/es not_active Application Discontinuation
-
2002
- 2002-06-27 IL IL150449A patent/IL150449A/en not_active IP Right Cessation
- 2002-07-30 ZA ZA200206072A patent/ZA200206072B/en unknown
- 2002-08-16 NO NO20023895A patent/NO329639B1/no not_active IP Right Cessation
-
2003
- 2003-01-03 HK HK03100094.2A patent/HK1047925B/zh not_active IP Right Cessation
-
2004
- 2004-08-30 US US10/930,360 patent/US7109164B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002123349A (ru) | Лиганды тироидного рецептора - производные анилина | |
JP2004500382A5 (ru) | ||
JP2004524261A5 (ru) | ||
US5013744B1 (en) | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity | |
KR970701698A (ko) | 프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists) | |
WO2000039077A3 (en) | Thyroid receptor ligands | |
HUT50153A (en) | Process for production of derivatives of acetylen disubstituated by phenil- and heterobicyclic group and medical compounds containing them as active substance | |
PT86442A (en) | Ethynylheteroaromatic acids having retinoic acid-like activity | |
KR880011068A (ko) | 이종방향족 그룹과 테트랄린 그룹으로서 이중 치환되고 레티노이드와 같은 작용성을 갖는 아세틸렌 | |
RU97106022A (ru) | Лиганды x-рецептора ретиноевой кислоты | |
ATE435202T1 (de) | Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung | |
JPS57185275A (en) | Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives | |
DE69603322T2 (de) | RAR-gamma-spezifische Retinobenzoesäurederivate | |
Jendralla et al. | Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3, 5-dihydroxyhexanoic acids | |
CA2118655A1 (en) | Parathyroid Hormone-Containing Emulsion for Nasal Administration | |
KR950000663A (ko) | 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질 | |
KR0171892B1 (en) | Process for the preparation of bromosubstituted aromatic esters of alfa beta unsaturated acids | |
IE44739B1 (en) | Adenine derivatives | |
IE883859L (en) | Novel antiarrhythmic agents i | |
CO4290296A1 (es) | Compuestos nitrato esteres de 1-ariloxi-3-alquilamino-2-pro- panoles, su utilizacion para la obtencion de un medicamento y la composicion farmaceutica correspondiente. | |
CA2304700A1 (en) | Lipophilic diesters of chelating agents | |
IL112432A0 (en) | Fatty acid derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
JPS55145650A (en) | Intermediate and its preparation | |
KR900009677A (ko) | 신규 화합물들 | |
EP0712838A4 (en) | ACYLPHENYLGLYCIN DERIVATIVE AND THIS PREVENTIVE AND HEALING AGENT CONTAINING ACTIVE SUBSTANCES AGAINST DISEASES CAUSED BY INCREASED COLLAGENASE ACTIVITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130113 |